CD8A and neoplasm: In vitro and in vivo studies showed that tumor-derived EVs expressing FasL and TRAIL activated regulatory T-cells and myeloid-derived suppressor cells (MDSCs), which prevented CD8+ T-cell from targeting the tumor [244].